Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-21
2008-09-09
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S143000, C544S295000, C544S357000, C544S373000, C546S200000, C546S277100, C548S181000, C548S235000, C548S537000, C549S059000, C549S473000
Reexamination Certificate
active
07423058
ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 7244721 (2007-07-01), Saksena et al.
patent: 2007/0032433 (2007-02-01), Saksena et al.
patent: 0 639 585 (1995-02-01), None
patent: 0 381 216 (1995-12-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 98/14181 (1998-04-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/08198 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 03/062265 (2003-07-01), None
patent: WO 03062265 (2003-07-01), None
patent: WO 2004/033425 (2004-04-01), None
Marchetti et al. “Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease” Synlett 1999, 1000-1002.
Berenguer, Marina, et al., “Hepatitis B and C Viruses: Molecular Identification and Targeted Antiviral Therapies”,Proceedings of the Association of American Physicians, 110(2):98-112 (1998).
Chen, Shu-Hui, et al., “Synthesis and Evaluation of Tripeptidyl α-Ketoamides as Human Rhinovirus 3C Protease Inhibitors”,Bioorganic&Medicinal Chemistry Letters, 13:3531-3536 (2003).
Dimasi, Nazzareno, et al., “Characterization of Engineered Hepatitus C Virus NS3 Protease Inhibitors Affinity Selected from Human Pancreatic Secretory Trypsin Inhibitor and Minibody Repertoires”,Journal of Virology, 71(10):7461-7469 (1997).
Elzouki, Abdul-Nasser, et al., “Serine Protease Inhibitors in Patients with Chronic Viral Hepatitis”,Journal of Hepatology, 27:42-48 (1997).
Failla, Cristina Maria, et al., “Redesigning the Substrate Specificity of the Hepatitus C Virus NS3 Protease”,Folding&Design, 1(1):35-42 (Jan. 10, 1996).
Han, Wei, et al., “α-Ketoamides, α-Ketoesters and α-Diketones as HCV NS3 Protease Inhibitors”,Bioorganic&Medicinal Chemistry Letters, 10:711-713 (2000).
Hoofnagle, Jay H., et al., “The Treatment of Chronic Viral Hepatitis”,Drug Therapy, 336(5):347-356 (1997).
Ingallinella, Paolo, et al. “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products”,Biochemistry, 37:8906-8914 (1998).
Kolykhalov, Alexander A., et al., “Specificity of the Hepatitis C Virus NS3 Serine Protease: Effects of Substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B Cleavage Sites on Polyprotein Processing”,Journal of Virology, 68(11):7525-7533 (Nov. 1994).
Komoda, Yasumasa, et al., “Substrate Requirements of Hepatitis C Virus Serine Proteinase for Intermolecular Polypeptide Cleavage inEscherichia coli”, Journal of Virology, 68(11):7351-7357 (Nov. 1994).
Lamar, Jason, et al., “Novel P4 truncated tripeptidyl α-ketoamides as HCV protease inhibitors”,Bioorganic&Medicinal Chemistry Letters, 14:263-266 (2004).
Landro, James A., et al., “Mechanistic Role of an NS4A Peptide Cofactor with the Truncated NS3 Proteaseof Hepatitis C Virus: Elucidation of the NS4A Stimulatory Effect via Kinetic Analysis and Inhibitor Mapping”,Biochemistry, 36:9340-9348 (1997).
Llinas-Brunet, Montse, et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease”,Bioorganic&Medicinal Chemistry Letters8:1713-1718 (1998).
Marchetti, Antonella, et al., “Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease”,Synlett, S1:1000-1002 (1999).
Martin, F., et al., “Affinity selection of a camelized VHdomain antibody inhibitor of hepatitis C virus NS3 protease”,Protein Engineering, 10(5):607-614 (1997).
Martin, Franck, et al., “Design of Selective Eglin Inhibitors of HCV NS3 Proteinase”,Biochemistry, 37:11459-11468 (1998).
Pizzi, Elisabetta, et al., “Molecular model of the specificity pocket of the hepatitis C virus protease: Implications for substrate recognition”,Proc. Natl. Acad. Sci. USA, 91:888-892 (Feb. 1994).
BioWorld Today, 9(217):1-5, (Nov. 10, 1998).
PCT International Search Report dated Jul. 29, 2005 for corresponding PCT Application No. PCT/US2005/006502.
Arasappan Ashok
Bennett Frank
Bogen Stephane L.
Chen Kevin X.
Girijavallabhan Viyyoor M.
Farquharson-Torres Serena
Kalyanaraman Palaiyur S.
Kosack Joseph R
Saeed Kamal A
LandOfFree
Inhibitors of hepatitis C virus NS3 protease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of hepatitis C virus NS3 protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of hepatitis C virus NS3 protease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3983269